Search results
Pfizer offers up to $250 million to settle thousands of Zantac cancer lawsuits, FT reports
WHTC 1450 Holland· 5 days ago(Reuters) - Pfizer has agreed offer payment of up to $250 million to settle more than 10,000...
Pfizer offers up to $250 million to settle Zantac cancer lawsuits, FT reports
AOL· 5 days agoThe drugmaker was set to pay between $200 million and $250 million in the settlement, the newspaper reported, citing two people briefed on the deal. The settlement was disclosed in a court filing ...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 1 day agoOctapharma USA, Inc. has appointed pharmaceutical industry veteran Kelly Hearn as Vice President of Commercial Development & Marketing, assuming immediate leadership of the product marketing ...
Pfizer offers up to $250 mln to settle thousands of Zantac cancer lawsuits, FT reports
Reuters· 5 days agoPfizer has agreed offer payment of up to $250 million to settle more than 10,000 lawsuits in the...
Moderna scores European victory over Pfizer and BioNTech in mRNA patent battle
Endpoints News· 4 days agoThe European Patent Office on Thursday handed a win to Moderna in a long-running patent battle with ...
2 Top Growth Stocks Down 24% and 50% to Buy With $100
Motley Fool via Yahoo Finance· 5 days agoIf you have even $100 to invest in stocks right now, here are two top healthcare companies that the...
Octapharma USA Appoints New VP of Commercial Marketing & Development
New Jersey Business Magazine· 1 day agoOctapharma USA, Inc. has appointed pharmaceutical industry veteran Kelly Hearn as vice president of...
Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in...
Morningstar· 5 days ago– After six months of additional follow-up, clinical benefit rate (63%), overall response rate (41.9%), median progression-free survival (11.2 months), and safety profile of vepdegestrant in ...
Vepdegestrant shows promise in breast cancer trial By Investing.com
Investing.com· 5 days agoArvinas, Inc. (NASDAQ: ARVN) and Pfizer Inc. (NYSE: NYSE:PFE) today announced continued positive...
Moderna Stock Rebounds From Its RSV Vaccine Fallout — Is It A Buy, Again?
Investor's Business Daily· 7 days agoIf approved, Moderna plans to launch the vaccine this fall for people age 60 and older. This puts it...